News

Categories
  1. Pseudobulbar Affect Treatments

    Pseudobulbar Affect (PBA) is a neurological condition that causes outbursts of uncontrolled or inappropriate laughing or crying. It is also known by other names including emotional lability, pathological laughing and crying, involuntary emotional expression disorder, compulsive laughing or weeping, or emotional incontinence.

    Read more »
  2. New Renal Cell Carcinoma Treatments 2021

    Renal cell carcinoma (RCC) also called kidney cancer or renal cell cancer is a disease in which malignant cancer cells are found in the lining of tubules in the kidney. RCC accounts for more than 80% of all kidney cancers.

    Read more »
  3. New Rheumatoid Arthritis Treatments 2021

    Rheumatoid arthritis (RA) is an autoimmune disease where the immune system attacks body tissues. It primarily affects joints, but it can also cause inflammation of organs, such as the lungs, eyes, skin, and heart.

    Read more »
  4. New Multiple Sclerosis Treatments 2021

    Multiple Sclerosis (MS) is a chronic, inflammatory, autoimmune disease of the central nervous system that disrupts communication between the brain and other parts of the body.

    Read more »
  5. New Parkinson’s Disease Treatments 2021

    Parkinson’s disease (PD) is a progressive brain disorder that causes shaking and muscle stiffness, and slows movement.

    Read more »
  6. New Colorectal Cancer Treatments 2021

    Colorectal cancer or colon cancer is cancer of the large intestine (colon), which is the final part of the digestive tract. Both colon cancer and rectal cancer can be referred to as colorectal or bowel cancer, but there is a slight difference between the two based on where the cancer begins.

    Read more »
  7. New ALS treatments 2021

    There are several ALS medications that are not yet approved in any country and currently under clinical trial. Read about the latest approved treatments.

    Read more »
  8. New HER2 Positive Breast Cancer Treatments 2021

    Human epidermal growth factor receptor 2 (HER2) is a growth-promoting protein on the outside of all breast cells. Breast cancer cells with higher than normal levels of HER2 are called HER2-positive.

    Read more »
  9. New Triple Negative Breast Cancer Treatments 2021

    Triple-negative breast cancer (TNBC) is a cancer that tests negative for progesterone and estrogen receptors, and excess HER2 protein. This means that the growth of the cancer is not fuelled by the estrogen and progesterone hormones, or by the HER2 protein. So, TNBC does not respond to hormonal therapy medicines or medicines that target HER2 protein receptors.

    Read more »
  10. What is Aimovig? | Information & Faq | TheSocialMedwork

    Aimovig (erenumab) is a preventive migraine treatment that works by blocking the activity of calcitonin gene-related peptide, a molecule that is involved in migraine attacks

    Read more »
  11. Newly approved medicines for Cystic Fibrosis

    Here is an overview of each medicine to help guide you and your physician when making a treatment decision for Cystic Fibrosis: 

    Read more »
  12. TheSocialMedwork commitment during the COVID-19 outbreak

    Here are some frequently asked questions and answers that touch on important COVID-19 related updates.

    Read more »
  13. What is Tudca? | Information & Faq | TheSocialMedwork

    5 common questions about the supplement that may be useful for ALS, Parkinson's and Alzheimers.

    Read more »
  14. Promising new data analysis for Alzheimer’s disease treatment

    New analysis of Biogen’s aducanumab shows reduction in clinical decline in Alzheimer’s disease.

    Xray of human brain

    Read more »
  15. New Parkinson's therapy approved by the FDA

    Kyowa Hakko Kirin's Parkinson's therapy, Nourianz (istradefylline), gains FDA approval as an add-on to levodopa/carbidopa.

    US flag thumbs up gesture

    Read more »
  16. China approves edaravone for ALS

    Radicut/Radicava (edaravone), shown to slow the progression of ALS, is now approved for patients in China.

    China flag thumbs-uo hand gesture

    Read more »
  17. SMC rejects two cystic fibrosis drugs

    Orkambi and Symkevi have been rejected by the Scotland Medicines Consortium (SMC) due to their conclusion that the costs outweigh the benefits.

    red haired girl on oxygen

    Read more »
  18. EMA recommends approval of Vitrakvi (larotrectinib)

    Vitrakvi (larotrectinib) recommended by the CHMP for approval in the EU.

    EU approval OK hand gesture

    Read more »
  19. MN-166 (ibudilast) to enter phase III clinical trials for progressive MS

    MN-166 (ibudilast) will be part of the Phase III clinical trial on progressive multiple sclerosis subjects with secondary progressive MS without relapses. 

    pipette samples

    Read more »
  20. Libtayo (cemiplimab): The only EU approved treatment for advanced CSCC

    New skin cancer medicine now approved in the EU for adults with metastatic or locally advanced cutaneous squamous cell carcinoma.

    EU approval OK hand gesture

    Read more »
  21. Phase 2 study: Ibudilast's effects in progressive MS

    Phase 2 clinical trial shows that ibudilast is linked to a 48% slowing in the progression of brain atrophy compared to placebo for patients with progressive MS.

    red mri brain scan

    Read more »
  22. Vyndaqel (tafamidis): Amyloidosis treatment approved by the FDA

    Vyndaqel (tafamidis) is now approved in the U.S. after study showed increased survivorship rate and reduced hospital time due to heart related problems.

    US flag thumbs up gesture

    Read more »
  23. FDA gives go-ahead for MN166 (ibudilast) to begin phase 2b/3 clinical trials

    Approval for next phase of clinical trials puts ALS patients one step closer to accessing new treatment shown to slow disease progression.

    FDA Ibudilast molecule and pills

    Read more »
  24. Kalydeco (ivacaftor) now approved in Canada for children aged 1-2

    Based on promising results from phase III clinical trials, Health Canada has decided to extend the use of Kalydeco (ivacaftor) to include children aged 1 to 2 years. 

    toddler in park with bubles

    Read more »
  25. Children with cystic fibrosis have a chance to breathe easier

    A recent clinical trial indicates that Symkevi/Symdeko (tezacaftor/ivacaftor) can safely and effectively loosen thick, sticky mucus for children 6-11 years old.

    girl running through field

    Read more »
  26. New cancer medicine targets tumour biomarkers anywhere in the body

    The new site-agnostic cancer medicine, Vitrakvi (larotrectinib), gets accelerated approval from the U.S. Food and Drug Administration (FDA).

    US flag thumbs up gesture

    Read more »
  27. Lung cancer medicine receives positive opinion in the EU

    CHMP's assessment supports EMA's approval of non-small cell lung cancer (NSCLC) medicine, Vizimpro (dacomitinib).

    EU approval OK hand gesture

    Read more »
  28. New study supports FDA's decision to approve Copiktra (duvelisib)

    Phase III trial shows that Copiktra (duvelisib) may be an option for patients with relapsed or refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma.

    woman smiling sunny

    Read more »
  29. Onpattro (patisiran): the first RNAi therapeutic approved in the European Union

    Onpattro (patisiran) is a first-in-class treatment that slows down the progression of hereditary transthyretin amyloidosis (hATTR).

    EU approval OK hand gesture

    Read more »
  30. Cancer medicine, Lartruvo (olaratumab), does not prolong life

    After failing to show a clear benefit over chemotherapy on its own, both the FDA and EMA do not recommend Lartruvo (olaratumab) for use in combination with chemotherapy for new STS patients.

    old bench

    Read more »
CA